Cancer

Francis Medical Announces First Patient Enrolled in VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer

MINNEAPOLIS (June 9, 2020) – Francis Medical, Inc., a Minneapolis-based, privately held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced the enrollment of their first patient in the company’s VAPOR 1 clinical study. VAPOR 1 is an early feasibility study evaluating the safety […]

Vyriad Inc. Names Experienced Life Sciences Investors Edwin Kania and Nathan Stacy to its Board of Directors

ROCHESTER, Minn., December 11, 2019 – Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of experienced life sciences investors Edwin M. Kania, Jr. and Nathan L. Stacy to the Company’s board of directors. Mr. Kania was named Chairman of the Board.  Mr. […]

Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer

Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments Vyriad to receive upfront payment and equity investment from Regeneron TARRYTOWN, N.Y., and ROCHESTER, Minn. (November 6, 2019) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Vyriad, Inc. today announced a research collaboration and option […]

Bio-Techne Releases 32×8 Cartridge for the Ella Platform

MINNEAPOLIS, July 17, 2019 /PRNewswire/ ‐‐ Bio‐Techne Corporation (NASDAQ: TECH) today announced the launch of a new 8‐Plex cartridge format for the ProteinSimple™‐branded Ella™ automated immunoassay platform. This new cartridge format analyzes 32 samples for eight distinct analytes, bringing higher multiplex capabilities to the Ella platform. The 32×8 cartridge for Ella enables users to build […]

Francis Medical Launches With $18M SERIES A Funding for Promising Cancer Ablation Technology Using Water Vapor

NxThera Acquired by Boston Scientific, Will Form New Cancer Therapy Company

On March 21st, Boston Scientific announced its intent to acquire Medical Alley-based NxThera, a medical device company developing the Rezūm system, a revolutionary, safe, and cost-effective minimally invasive treatment option for men suffering from benign prostatic hyperplasia (BPH). “We are excited to announce this agreement with Boston Scientific,” said Bob Paulson, president and chief executive […]

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER